SCHEMBL20280504

SCHEMBL20280504

CC(C)(C)c1ccc(O)c(/N=N/c2nccs2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.68
HSP90AA1 P07900 2/20 0.68
CCR6 P51684 1/20 0.68
KMT2A Q03164 8/20 0.56
MAPT P10636 7/20 0.56
MEN1 O00255 6/20 0.56
KDM4E B2RXH2 5/20 0.56
TDP1 Q9NUW8 3/20 0.56
POLB P06746 3/20 0.56
MAPK1 P28482 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
IDO1 P14902 1/20 0.56
TDO2 P48775 1/20 0.56
GFER P55789 1/20 0.56
RAB9A P51151 2/20 0.48
PAX8 Q06710 1/20 0.48
KCNH2 Q12809 1/20 0.48
RIOK2 Q9BVS4 1/20 0.48
ALDH1A1 P00352 5/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728387 0.81 L3MBTL1 (1.00) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL5728388 0.81 L3MBTL1 (1.00) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL27589733 0.78 L3MBTL1 (0.69) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL20280307 0.78 L3MBTL1 (0.69) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL20280046 0.78 L3MBTL1 (0.69) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL20280358 0.78 L3MBTL1 (0.68) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL18645426 0.78 L3MBTL1 (0.68) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL20280490 0.78 L3MBTL1 (0.68) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL11475446 0.78 L3MBTL1 (0.68) L3MBTL1HSP90AA1CCR6KMT2AMAPT
SCHEMBL13994757 0.75 ALDH1A1 (0.41) L3MBTL1HSP90AA1CCR6KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3347001-B1 AZOPHENOLS AS ERG ONCOGENE INHIBITORS HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC (US) 2023-07-26 EP disclosed
US-10238639-B2 Azophenols as ERG oncogene inhibitors THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2019-03-26 US disclosed
US-20180169074-A1 Azophenols as ERG Oncogene Inhibitors THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180169074-A1 Azophenols as ERG Oncogene Inhibitors ERG, ESR1, CBX2 L3MBTL1 2210/4885HSP90AA1 4047/4885CCR6 3626/4885
US-10238639-B2 Azophenols as ERG oncogene inhibitors ERG, ESR1, CBX2 L3MBTL1 2210/4885HSP90AA1 4047/4885CCR6 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.